These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination]. Topuzova MP; Bisaga GN; Alekseeva TM; Isabekova PS; Сhaykovskaya AD; Panina EB; Pavlova TA; Ternovykh IK Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):97-106. PubMed ID: 32844638 [TBL] [Abstract][Full Text] [Related]
6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M; J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675 [TBL] [Abstract][Full Text] [Related]
7. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978 [TBL] [Abstract][Full Text] [Related]
8. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]
9. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data. Kopp CR; Prasad CB; Naidu S; Sharma V; Misra DP; Agarwal V; Sharma A Lupus; 2023 Sep; 32(10):1164-1172. PubMed ID: 37487596 [TBL] [Abstract][Full Text] [Related]
10. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288 [TBL] [Abstract][Full Text] [Related]
11. Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Katsumata Y; Kawachi I; Kawaguchi Y; Gono T; Ichida H; Hara M; Yamanaka H Mod Rheumatol; 2012 Sep; 22(5):676-84. PubMed ID: 22183613 [TBL] [Abstract][Full Text] [Related]
12. Clinical features of transverse myelitis associated with systemic lupus erythematosus. Zhang S; Wang Z; Zhao J; Wu DI; Li J; Wang Q; Su J; Xu D; Wang Y; Li M; Zeng X Lupus; 2020 Apr; 29(4):389-397. PubMed ID: 32054395 [TBL] [Abstract][Full Text] [Related]
13. Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. Kunchok A; Flanagan EP; Snyder M; Saadeh R; Chen JJ; Weinshenker BG; McKeon A; Pittock SJ Mult Scler; 2021 Apr; 27(4):630-635. PubMed ID: 32633603 [TBL] [Abstract][Full Text] [Related]
14. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206 [TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia. Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527 [TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750 [TBL] [Abstract][Full Text] [Related]
18. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159 [TBL] [Abstract][Full Text] [Related]
19. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314 [TBL] [Abstract][Full Text] [Related]
20. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Alexopoulos H; Kampylafka EI; Fouka P; Tatouli I; Akrivou S; Politis PK; Moutsopoulos HM; Tzioufas AG; Dalakas MC J Neuroimmunol; 2015 Dec; 289():8-11. PubMed ID: 26616866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]